| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to organic chemistry, namely to a new compound of formula or its pharmaceutically acceptable salt, wherein R 1 represents (C 1 -C 6 )alkyl; an oxodihydropyridyl ring in the formula is optionally substituted by 1-3 groups optionally specified in fluorine, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 4 -C 7 )cycloalkylalkyl, halo(C 1 -C 6 )alkyl and (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy; R 2 represents (C 1 -C 6 )alkyl, phenyl, or tetrahydropyranyl optionally substituted by a group in the number of up to 1 independently specified in fluorine, hydroxy(C 1 -C 6 )alkyl and (C 3 -C 6 )cycloalkyl; R 3 is specified in (C 1 -C 6 )alkyl optionally substituted by groups in the number of up to 3 independently specified in fluorine, cyano, R 4 , R 4 O-, (R 4 ) 2 N-, R 4 C(=O)NR 4 -, (R 4 ) 2 NC(=O)-, R 4 OC(=O)NR 4 -, R 4 S(=O) 2 NR 4 - and oxadiazolyl optionally substituted by (C 1 -C 6 )alkyl; R 4 independently represents H or (C 1 -C 6 )alkyl. Also, the invention refers to a method of treating an individual by using the above compound, a method of inhibiting 11β-HSD1, and a compound-based pharmaceutical composition. n EFFECT: there are prepared new compounds effective in treating the diseases related to 11β-HSD1 activity or expression. n 15 cl, 6 tbl, 101 ex |